Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Clene’s nanocrystal breakthrough is exciting—decoding its SEC paperwork is not. Each 10-K details millions in R&D for CNM-Au8, every 8-K flags trial readouts, and Form 4 insider trades hint at executive confidence. Finding those nuggets across hundreds of pages is the real challenge.
Stock Titan solves that problem. Our AI-powered summaries break down Clene SEC filings explained simply, highlighting cash runway, NIH grant inflows, and milestone payments in seconds. Whether you search "How to read Clene’s 10-K annual report" or "Where can I find Clene’s quarterly earnings report 10-Q filing?", you land on real-time documents the moment they post to EDGAR—already analyzed.
Here’s what you’ll uncover faster:
- 10-Q & 10-K: R&D spend, liquidity outlook, and nanocrystal manufacturing costs—Clene annual report 10-K simplified.
- Form 4: Clene insider trading Form 4 transactions and executive stock moves, delivered as "Clene Form 4 insider transactions real-time" alerts.
- 8-K: Clinical data drops and financing updates—Clene 8-K material events explained.
- DEF 14A proxy: Clene proxy statement executive compensation and milestone-based pay structures.
Stop skimming PDFs and start asking bigger questions: "understanding Clene SEC documents with AI" or "Clene earnings report filing analysis." Our platform turns complex biotech disclosure into clear, actionable insight so you can decide—quickly—whether Clene’s next catalyst merits attention.
LandBridge Company LLC (LB) – Insider Form 4 Filing
Executive Vice President & Chief Administrative Officer Jason Frederick Williams filed a Form 4 covering activity on 1 July 2025. The filing discloses that 9,757 Class A shares were withheld and automatically disposed of at an indicated price of $66.38 per share. The transaction is coded “F”, meaning the shares were surrendered solely to satisfy federal and state tax-withholding obligations on the vesting of previously granted restricted share units (RSUs) under the company’s Long-Term Incentive Plan. No open-market sale or purchase occurred.
Following the tax-related share withholding, Williams’ direct beneficial ownership stands at 64,633 Class A shares. The filing lists no new derivative securities, option exercises or additional equity grants.
Because the disposition was mandatory for tax purposes, it does not necessarily signal a change in Williams’ view of the company’s prospects. Investors typically view Code F transactions as neutral relative to discretionary insider buying or selling, although they still modestly increase public float by releasing shares into the market.
ICF International (ICFI) Form 4 filing: Director Michael J. Van Handel acquired 1,720 shares of common stock on 1 Jul 2025 through a restricted stock unit (RSU) grant under the company’s Amended and Restated 2018 Omnibus Incentive Plan. The RSUs carry a zero-dollar exercise price and will vest in equal quarterly increments on Sept 1, Dec 1, Mar 1 and Jun 1. Following the award, the director’s direct holdings rise to 16,254 shares. No derivative security activity was reported.
iShares BB Rated Corporate Bond ETF, a series of iShares Trust, filed its routine Form NPORT-P for the monthly period ended 30-Apr-2025.
The fund reported total assets of $286.0 million, liabilities of $81.6 million, and net assets of $204.4 million. No borrowings were outstanding and no controlled foreign corporations were used. Cash and cash equivalents not otherwise disclosed totaled $0.20 million.
Interest-rate DV01 exposure in U.S. dollars was modest, led by the 5-year bucket at $26.96 thousand; a 100-bp parallel shift (DV100) would change portfolio value by $5.17 million in the 5-year tenor. Credit-spread sensitivity shows the portfolio is predominately non-investment-grade, with a 5-year CS01 of $55.35 thousand.
The fund is active in securities lending: across 20 counterparties, securities on loan totaled roughly $38.8 million (≈19% of net assets). Largest borrowers include Barclays Bank plc (~$9.0 m), BNP Paribas Prime Brokerage (~$7.25 m) and RBC Capital Markets (~$6.30 m). The filing indicates that some counterparties provided non-cash collateral, though exact amounts were not disclosed.
No preferred stock is outstanding, and the filing does not indicate that this will be the fund’s final NPORT-P submission.
FAQ
What is the current stock price of Clene (CLNN)?
What is the market cap of Clene (CLNN)?
What is Clene Inc.'s core technology?
What diseases is Clene targeting?
What is CNM-Au8®?
What sets Clene apart from competitors?
How does Clene generate revenue?
What is Clene’s regulatory strategy?
What are Clene’s safety findings for CNM-Au8®?
Who are Clene’s key collaborators?
What is the potential market impact of CNM-Au8®?
How does Clene contribute to real-world evidence in ALS?
